department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Ubrelvy · pharmadog

pharmadog
drugs
Ubrelvy

drug · small molecule

patient view →

ubrogepant

Marketedupdated 2mo ago

by $ABBV AbbVie Inc.🔗 ChEMBL

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval, with an approval for migraine disorder.

targets

Calcitonin gene-related peptide type 1 receptor

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Ubrelvy

trade names

Ubrelvy

generic

ubrogepant

MOA

Calcitonin gene-related peptide type 1 receptor antagonist

indication

Migraine

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 53m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Nov 10, 2031

~5.3 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (27)

Dec 22, 2041method-of-use (U-3677)US 11717515
Dec 22, 2041method-of-use (U-3786)US 11857542
Dec 22, 2041method-of-use (U-3992)US 12070450
Dec 22, 2041method-of-use (U-4122)US 12194030
Dec 22, 2041method-of-use (U-4213)US 12329750
Jan 30, 2035formulationUS 10117836
Jan 30, 2035formulationUS 10117836
Jan 30, 2035formulationUS 11925709
Jan 30, 2035formulationUS 11925709
Jan 30, 2035formulationUS 12168004
Jan 30, 2035formulationUS 12168004
Jan 30, 2035formulationUS 12220408
Jan 30, 2035formulationUS 12220408
Jan 30, 2035formulationUS 12310953
Jan 30, 2035formulationUS 12310953
Jan 30, 2035formulationUS 12458632
Jan 30, 2035formulationUS 12458632
Jan 30, 2035formulationUS 12458633
Jan 30, 2035formulationUS 12458633
Dec 23, 2033compositionUS 8912210
Dec 23, 2033compositionUS 8912210
Jul 19, 2032compositionUS 8754096
Jul 19, 2032compositionUS 8754096
Nov 10, 2031compositionUS 9499545
Nov 10, 2031compositionUS 9499545
Nov 10, 2031method-of-use (U-2718)US 9833448
Nov 10, 2031method-of-use (U-2718)US 9833448

Trials studying ubrogepant

phase3Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)recruitingn=1,059
phase3Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migrainerecruitingn=496
phase1A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migrainecompletedn=43
phase3Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)enrolling by invitationn=1,200
phase4Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migrainecompletedn=263
phase4Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodiesactive not recruitingn=164
phase1Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteerscompletedn=24
phase3Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participantscompletedn=518

more trials →